1 of azithromycin in the treatment of COVID-
19 remain uncertain.
2 agnitude of any changes in atmospheric pO(
2)
remain uncertain.
3 and spreading, but its mechanisms of
action remain uncertain.
4 ng modifier signal whose mechanism of
action remains uncertain but does not involve an amino acid cha
5 ssion by anemia, but its mechanism of
action remains uncertain.
6 thognomonic transient complement
activation,
remains uncertain.
7 ut the origin and functions of this
activity remain uncertain.
8 mplications for future thunderstorm
activity remain uncertain.
9 dentate mossy cells on hippocampal
activity remained uncertain despite a long history of investigati
10 -19 outcomes- particularly in younger
adults-
remains uncertain.
11 iagnosis, age at diagnosis, and attained
age remains uncertain.
12 e over time, but the influence of forest
age remains uncertain.
13 Although the true risk of CI-
AKI remains uncertain for patients with severe kidney diseas
14 alt the extension of related cross-
allergies remains uncertain.
15 the long-term durability of DCB
angioplasty remains uncertain.
16 ences between the two therapeutic
approaches remains uncertain.
17 in antiphospholipid antibody syndrome (
APS)
remains uncertain.
18 h acute respiratory distress syndrome (
ARDS)
remain uncertain.
19 in the aetiology of acute scrotal pain (
ASP)
remains uncertain.
20 cohorts that can be realistically
assembled remains uncertain.
21 e direction and magnitude of the
association remain uncertain.
22 lly modifiable exposures that lead to
asthma remain uncertain.
23 development of recurrent wheezing and
asthma remains uncertain, particularly in the high-risk group o
24 in global temperature and water
availability remains uncertain.
25 umor growth, but the relevance of vitamin
B6 remains uncertain.
26 ism spectrum disorder (ASD), its brain
bases remain uncertain.
27 Thus, population-wide distributions of
BC remain uncertain.
28 total carbon fixation allocated
belowground remain uncertain.
29 nsplant models, but whether it is
beneficial remains uncertain.
30 for eligible patients; however, the
benefit remains uncertain in the rituximab era.
31 , as well as the impact of sex on this
bias,
remain uncertain.
32 Although the mechanisms driving
BPD remain uncertain, exposure to hyperoxia is thought to co
33 est fire on Earth's surface radiative
budget remain uncertain at the global scale.
34 tions may take at least five more years,
but remains uncertain for the deeper reefs.
35 treatment of patients with esophageal
cancer remains uncertain.
36 enhance anti-PD-1 therapy activity in
cancer remains uncertain.
37 eplacement therapy (TRT) and prostate
cancer remains uncertain.
38 visibility and invisibility of these
cancers remain uncertain.
39 r CHD but the cause in the majority of
cases remains uncertain.
40 these observational associations are
causal remains uncertain.
41 isk; however, whether the relation is
causal remains uncertain.
42 The physiological
causes remain uncertain, although impaired myometrial function
43 stem/progenitors other than basal-like
cells remains uncertain.
44 How this is realized in 21st
century remains uncertain, in large part due to limitations on p
45 of soil respiration to precipitation
changes remain uncertain in terrestrial ecosystems.
46 of these signals-whether thermal or
chemical-
remain uncertain, and therefore much of the information
47 respiratory outcomes during early
childhood remains uncertain.
48 changes associated with dietary
cholesterol remain uncertain.
49 calcification and arterial stiffness in
CKD remain uncertain.
50 sphorus loads, the impacts of future
climate remain uncertain.
51 ns of these changes for mid-latitude
climate remain uncertain(5,6).
52 hanges in TC activity under a warmer
climate remain uncertain, particularly in terms of TC genesis lo
53 imate Model Intercomparison Project (
CMIP5),
remain uncertain.
54 e, but their performance in external
cohorts remains uncertain.
55 interactions with different LHCII
complexes remain uncertain.
56 species , yet the source of these
compounds remains uncertain.
57 , but its efficacy and optimal
concentration remain uncertain.
58 s across climatic and geochemical
conditions remain uncertain.
59 borne disease, but its clinical
consequences remain uncertain.
60 of VIP cell output to physiological
control remains uncertain.
61 ons, although the evidence for their
control remains uncertain.
62 o hepcidin production by other systemic
cues remain uncertain.
63 potential for this strategy to achieve
cure remains uncertain.
64 eased risk of cerebrovascular accident (
CVA)
remains uncertain.
65 and implications for the global water
cycle remain uncertain.
66 although the magnitude of future
decoupling remains uncertain.
67 r mechanisms leading to retinal
degeneration remain uncertain, although previous studies have shown t
68 threshold value associated with
deglaciation remains uncertain.
69 chemistry, lifetime, and surface
deposition remains uncertain.
70 The risk associated with insulin
detemir remains uncertain because there are fewer users of this
71 enesis, but its role in coronary
development remains uncertain.
72 n humans, the mechanism by which it
develops remains uncertain.
73 to be inherited, but in many cases
diagnosis remains uncertain.
74 G imaging (ECGI) in structural heart
disease remains uncertain.
75 revention of multifactorial chronic
diseases remains uncertain, and there is sparse evidence regardin
76 ent to which they are functionally
distinct,
remain uncertain.
77 ation of nuclear proteins, but damage to
DNA remains uncertain, as does any effect on cell cycle.
78 circumstances that facilitate
domestication remain uncertain.
79 ting their maintenance or exit from
dormancy remain uncertain.
80 the impact of transcatheter valve
durability remains uncertain.
81 endence of respiration in aquatic
ecosystems remain uncertain.
82 The carbon balance of tropical
ecosystems remains uncertain, with top-down atmospheric studies sug
83 est, but its outcomes and cost-
effectiveness remain uncertain.PurposeTo determine if biennial DBT is
84 ut their long-term comparative
effectiveness remains uncertain.
85 for frozen shoulder, but their
effectiveness remains uncertain.
86 mechanisms underlying its anesthetic
effects remain uncertain.
87 chanisms underlying these pathogenic
effects remain uncertain.
88 treatment of chronic pain, yet its
efficacy remains uncertain.
89 utism spectrum disorders, but their
efficacy remains uncertain.
90 plication pathways, but their mode of
egress remains uncertain.
91 h work, the mechanisms by which bnAbs
emerge remain uncertain.
92 associated nitrous oxide (N(2) O)
emissions remain uncertain.
93 ions in controlling Arctic methane
emissions remains uncertain.
94 -term, regional trends in
evapotranspiration remain uncertain due to spatially and temporally limited
95 ents among those surviving a first CAD
event remain uncertain, with possible biological differences b
96 subsurface/atmospheric natural gas
exchange remain uncertain.
97 The mechanism of PS
exposure remains uncertain but it can follow increased intracellu
98 of their ecology, evolution, and
extinction remain uncertain.
99 ecular mechanism underlying lysosome
fission remains uncertain.
100 l-floor topography on the cataclysmic
floods remains uncertain.
101 its sensitivity to external climate
forcing remains uncertain.
102 nase activity in the process of CO
formation remains uncertain.
103 in autoimmune uveitis, their exact
function remains uncertain.
104 ny additional benefits to physical
function,
remains uncertain.
105 implications for real-world soil
functioning remain uncertain.
106 iochemical levels, their in planta
functions remain uncertain.
107 hese interactions might change in the
future remain uncertain.
108 utcomes, but optimal gestational weight
gain remains uncertain and not well defined for all prepregna
109 protein ubiquitylation to peptide
generation remains uncertain.
110 hese responses along environmental
gradients remain uncertain.
111 (2) and climate during the Eocene
greenhouse remains uncertain.
112 e in driving patterns of vegetative
greening remain uncertain.
113 tion over space, time, and stakeholder
group remain uncertain.
114 pindle afferents, the selective role of
GTOs remains uncertain.
115 ole of interleukin (IL)-17 and IL-22 in
GVHD remains uncertain, due to an apparent lack of lineage fi
116 It
has remained uncertain whether the mechanisms of visual perc
117 tory disorders, including PAMI syndrome,
has remained uncertain.
118 echanisms behind this directed movement
have remained uncertain.
119 ces of chronic insufficient sleep for
health remain uncertain.
120 sive blood pressure lowering on brain
health remains uncertain.
121 fat content influence cardiovascular
health remains uncertain.
122 ons of exposure to bullying to mental
health remains uncertain, as noncausal relationships may arise
123 thern Oscillation (ENSO) during the
Holocene remains uncertain.
124 of intensive care unit (ICU) visiting
hours remain uncertain.
125 he development of childhood asthma,
however,
remains uncertain.
126 The lifespan of brain microglia,
however,
remains uncertain, and reflects confounding factors in e
127 ry on patients with obesity and
hypertension remain uncertain.
128 for BP in patients with CKD and
hypertension remains uncertain.
129 port in the oceans, although the net
impacts remain uncertain.
130 py, but their relative prognostic
importance remains uncertain.
131 thways for early-onset myocardial
infarction remain uncertain.
132 l neoplasia (CIN); however, causal
inference remains uncertain.
133 s influence individual-level food
insecurity remains uncertain.
134 tors (TFs), but how TFs dynamically
interact remains uncertain.
135 ular details of the PrP(C)-Abeta
interaction remain uncertain.
136 eglaciation; however, the processes
involved remain uncertain.
137 nce and effector pathway locally in the
iris remain uncertain.
138 It remains uncertain how the global processes of WPE and cl
139 It remains uncertain though which hosts they rely upon, and
140 It remains uncertain whether BMAs should be discontinued be
141 It remains uncertain whether kidney transplant recipients a
142 It remains uncertain whether prophylactic exclusion of the
143 It remains uncertain whether prototypical facial features i
144 It remains uncertain whether the association between CRP co
145 It remains uncertain whether the omega-3 fatty acids eicosa
146 It remains uncertain, however, how it relates to amyloid an
147 It remains uncertain, however, to what extent biogeochemica
148 It remains uncertain, however, to what extent temperature a
149 It remains uncertain, however, whether BAT (18)F-FDG uptake
150 It remains uncertain, however, whether tree mortality acros
151 e for such a role is sparse, however, and
it remains uncertain how that role relates to the disparate
152 even a formal [4 + 2] cycloaddition, and
it remains uncertain if any of them proceed via the Diels-A
153 n about paracellular HCO(3) (-) flux, and
it remains uncertain whether an acidic pH produced by loss
154 sease (CHD) and type 2 diabetes (T2D) but
it remains uncertain if glycine plays an aetiological role.
155 Furthermore,
it remains uncertain which joint cells and SASP-factors con
156 However,
it remains uncertain how drought resistance and resilience
157 nsitivity to biological changes, however,
it remains uncertain how these measures are associated.
158 However,
it remains uncertain how to best utilize these strategies i
159 m electronic-vibrational mixing, however,
it remains uncertain if such mixing significantly influence
160 However,
it remains uncertain if ZIKV infection in pregnancy also in
161 However,
it remains uncertain where the initial alpha-synuclein aggr
162 However,
it remains uncertain whether its autophagic activity is ass
163 However,
it remains uncertain whether modified nucleosomes play a ca
164 However,
it remains uncertain whether recovered organic residues rep
165 However,
it remains uncertain whether the adverse cognitive conseque
166 tion in a tissue factor-dependent manner,
it remains uncertain whether stimulated neutrophils can als
167 ected non-small-cell lung cancer (NSCLC),
it remains uncertain whether this approach is superior to s
168 us cycle over the past 3.5 billion years,
it remains uncertain whether phosphorus limitation persiste
169 While the mechanistic etiology of
JBS remains uncertain, mutation of both Ubr1 and Ubr2 in the
170 much Antarctica will contribute to sea
level remains uncertain, but multimeter sea level rise is like
171 sms responsible for associated carbon
losses remain uncertain.
172 derstanding T globally, while the
magnitudes remain uncertain.
173 s of ERT on renal and cardiac
manifestations remain uncertain and thus novel therapies are desirable.
174 re, but its provenance in the Earth's
mantle remains uncertain.
175 hepcidin through a BMP2-dependent
mechanism remain uncertain.
176 er, the underlying disease-causing
mechanism remains uncertain.
177 sion, yet the underlying molecular
mechanism remains uncertain.
178 mere replication but the molecular
mechanism remains uncertain.
179 ons; yet, the underlying biologic
mechanisms remain uncertain.
180 valence of diabetes; however, the
mechanisms remain uncertain.
181 However, underlying
mechanisms remain uncertain because the partial contributions of th
182 t enable the consolidation of motor
memories remain uncertain.
183 eir impact on the gut's bacterial
microbiota remains uncertain.
184 However, the precise mechanisms of
mitophagy remain uncertain.
185 deviations from a mean cell size at
mitosis remains uncertain.
186 ical meaning of MRD in multiple myeloma (
MM)
remains uncertain, particularly when assessed by next-ge
187 ts in reducing clinical sepsis and
mortality remain uncertain.
188 ude of risk reduction of perinatal
mortality remains uncertain.
189 brain injury, the prognostic utility of
MRI remains uncertain.
190 Because of limited data,
much remains uncertain about parameters related to transmissi
191 earth's magnetic field, yet in sharks,
much remains uncertain regarding the sensory receptors and pa
192 essential functions of the salience
network remain uncertain.
193 mechanism how Notch works in mature
neurons remains uncertain.
194 own products to plant nitrogen (N)
nutrition remains uncertain.
195 on trends and the disease burden of
obesity remain uncertain.
196 , the precise mechanism by which this
occurs remains uncertain.
197 tions of the three C-terminal domains of
OPG remain uncertain.
198 ng modality, and current therapeutic
options remain uncertain but are rapidly evolving.
199 cutaneous therapies but its clinical
outcome remains uncertain.
200 y; however, its effects on clinical
outcomes remain uncertain.
201 c of ongoing debate and medium-term
outcomes remain uncertain.
202 fonylurea therapy on cardiovascular
outcomes remains uncertain.
203 delines, but its effect on clinical
outcomes remains uncertain.
204 ; however, their effect on clinical
outcomes remains uncertain.
205 ing, and whether it yields improved
outcomes remains uncertain.
206 bidities in young children, the
pathobiology remains uncertain.
207 driver in motor neuron disease
pathogenesis remains uncertain.
208 al symptom of HFpEF, yet its
pathophysiology remains uncertain.
209 been extensively investigated, loss
pathways remain uncertain.
210 red with SAVR for intermediate-risk
patients remains uncertain.
211 VR, the optimal management of these
patients remains uncertain and controversial.
212 ter percutaneous coronary intervention (
PCI)
remains uncertain, with some studies finding in favor of
213 optimal treatment for many phenotypes of
PE remains uncertain.
214 As a result, the utility of this
phenomenon remains uncertain.
215 d functional significance in vascular
plants remain uncertain.
216 bundant sterol derivatives in higher
plants,
remains uncertain.
217 hip between neural and behavioral
plasticity remains uncertain.
218 , effectiveness of land consolidation
policy remains uncertain.
219 rapy, and outcomes by sex in this
population remain uncertain.
220 he status of the fish within each
population remains uncertain.
221 y-related diseases in the general
population remains uncertain.
222 ert Ultra cartridge in different
populations remain uncertain.
223 merican, Inuit, Yup'ik and Aleut
populations remains uncertain(4-6).
224 IV-1) in demographically diverse
populations remains uncertain.
225 ease, but its functional oncogenic
potential remains uncertain.
226 eneralizability to routine clinical
practice remains uncertain.
227 ing RAD51D variants to cancer
predisposition remains uncertain.
228 interactions, whose existence and
prevalence remains uncertain.
229 bsequently recovered, but future
projections remain uncertain.
230 pe bacterial and archaeal genomic
properties remain uncertain (3-7) .
231 s are confounding materials whose
properties remain uncertain, even after years of study.
232 ffectiveness of its use in patients with
PSC remain uncertain, with only a few studies performed on t
233 oxidation catalysis, the active phase of
Pt remains uncertain, even for the Pt(111) single-crystal s
234 of plant traits to predict demographic
rates remains uncertain, particularly in the context of trees
235 the regulation of TGF-beta type II
receptor remains uncertain.
236 ts accumulate and promote liver
regeneration remain uncertain.
237 associations represent causal
relationships remains uncertain.
238 collapse in stock-recruitment
relationships remains uncertain, given the projected increased frequen
239 e subtle changes, whose functional
relevance remains uncertain, were not accompanied by any discernib
240 n (SOC) losses via heterotrophic
respiration remains uncertain, in part because different or even opp
241 details of how uncoupled forks are
restarted remain uncertain.
242 the role of the counterion cluster of
RPSB,
remain uncertain.
243 osed, the true biological function of
Rv3802 remains uncertain.
244 ify at food web, regional, and global
scales remains uncertain.
245 abnormal brain morphometry in
schizophrenia remains uncertain.
246 the overall cost-effectiveness of
screening remains uncertain.
247 the strategies that confer such
selectivity remain uncertain.
248 symptomatic secondary immunodeficiency (
SID)
remain uncertain.
249 s well-established, the drivers of this
sink remain uncertain.
250 he long-term trend of the northern land
sink remains uncertain.
251 dispersal ability and geographic range
size remains uncertain, particularly in mammals.
252 om positive to negative among plant
species,
remain uncertain.
253 the chronological age of many key
specimens remains uncertain.
254 ment elevation myocardial infarction (
STEMI)
remains uncertain.
255 ronary intervention with drug-eluting
stents remains uncertain.
256 exact nature and quantitation of HBeAg
still remain uncertain.
257 tures that lead to efficient PRF
stimulation remain uncertain.
258 efficacy of these interventional
strategies remains uncertain.
259 ity, but the appropriate management
strategy remains uncertain.
260 ver, the most appropriate follow-up
strategy remains uncertain.
261 nique in patients with acute ischemic
stroke remain uncertain because of lack of evidence from random
262 age (ICH) in patients with a previous
stroke remains uncertain.
263 omising, results from these previous
studies remain uncertain because of potential selection bias.
264 s cancers, but the impact of further
studies remains uncertain.
265 s to populations and to longer-term
survival remains uncertain.
266 people with different genetic
susceptibility remains uncertain.
267 usceptibility to clinical infection
symptoms remains uncertain.
268 , yet its efficacy in treating PTSD
symptoms remains uncertain.
269 ve-compulsive disorder and Tourette
syndrome remain uncertain.
270 patients with recent acute coronary
syndrome remains uncertain.
271 ism of Earth's plate tectonic cooling
system remains uncertain.
272 rocesses in vivo and are therapeutic
targets remains uncertain.
273 tion with conventional diagnostic
technology remains uncertain despite several studies reporting impr
274 r, reconstructions of LIG global
temperature remain uncertain, with estimates ranging from no signifi
275 from intensification of antiplatelet
therapy remains uncertain.
276 Clinicians
therefore remain uncertain regarding when to commence DOAC adminis
277 at regional or country-wide scales
therefore remain uncertain.
278 ction, but the clinical implications of
this remain uncertain.
279 Nevertheless,
this remains uncertain when receiving a kidney from a donor >
280 it ratio of postdischarge
thromboprophylaxis remains uncertain, randomized controlled trials to evalu
281 nce on 1,000-year to 100,000-year
timescales remains uncertain(4).
282 d by key baseline characteristics and
timing remains uncertain.
283 ease or are beneficial in COVID-19
treatment remains uncertain.
284 in AF, the optimal antithrombotic
treatment remains uncertain for primary protection against MI.
285 local versus remote breaking into
turbulence-
remains uncertain.
286 worldwide, yet associations between the
two remain uncertain.
287 nfection via single genome samples
typically remains uncertain.
288 conditions, but the safety of long-term
use remains uncertain.
289 mes but the economic case for widespread
use remains uncertain.
290 are clinically used; however, their
validity remains uncertain considering ongoing changes in the pan
291 ibrillation and a bioprosthetic mitral
valve remain uncertain.
292 ntensity for patients with mechanical
valves remains uncertain; current recommendations are inconsist
293 ctating their formation and function in
vivo remains uncertain.
294 neutralization when transmitting through
VS remains uncertain.
295 ween GDF-15 and venous thromboembolism (
VTE)
remains uncertain.
296 n women with suspected pre-eclampsia, but
we remain uncertain of the effectiveness of these tests in
297 long-term continued survival of right
whales remains uncertain.
298 ple processes, the combined effects of
which remain uncertain, particularly in the tropics.
299 e understanding of virus transmission,
which remains uncertain.
300 e results suggest program effectiveness
will remain uncertain in the absence of requiring monitoring